Self management of oral anticoagulation: randomised trial.
OBJECTIVE
To determine the clinical effectiveness of self management compared with routine care in patients on long term oral anticoagulants.


METHODS
Multicentre open randomised controlled trial.


METHODS
Midlands region of the UK.


METHODS
617 patients aged over 18 and receiving warfarin randomised to intervention (n = 337) and routine care (n = from 2470 invited; 193/337 (57%) completed the 12 month intervention.


METHODS
Intervention patients used a point of care device to measure international normalised ratio twice a week and a simple dosing chart to interpret their dose of warfarin.


METHODS
Percentage of time spent within the therapeutic range of international normalised ratio.


RESULTS
No significant differences were found in percentage of time in the therapeutic range between self management and routine care (70% v 68%). Self managed patients with poor control before the study showed an improvement in control that was not seen in the routine care group. Nine patients (2.8/100 patient years) had serious adverse events in the self managed group, compared with seven (2.7/100 patient years) in the routine care arm (chi2(df = 1) = 0.02, P = 0.89).


CONCLUSIONS
With appropriate training, self management is safe and reliable for a sizeable proportion of patients receiving oral anticoagulation treatment. It may improve the time spent the therapeutic range for patients with initially poor control. Trial registration ISRCTN 19313375.
Fitzmaurice
D A
DA
Department of Primary Care, University of Birmingham, Birmingham. d.a.fitzmaurice@bham.ac.uk
Murray
E T
ET
McCahon
D
D
Holder
R
R
Raftery
J P
JP
Hussain
S
S
Sandhar
H
H
Hobbs
F D R
FD
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D019095:Point-of-Care Systems; D012648:Self Care / Q000379:methods*; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
D000925:Anticoagulants; D014859:Warfarin